Lack of Trust in Government Fueled COVID-19 Vaccine Hesitancy, Inquiry Finds

A lack of trust in government was a “significant contributor” to COVID-19 vaccine hesitancy in some UK communities, according to a comprehensive report released Thursday by the UK COVID-19 Inquiry.

Led by Baroness Hallett, the inquiry found that while Britain’s vaccine rollout was largely successful, distrust in authorities and susceptibility to misinformation hindered uptake in certain demographics, particularly in areas of higher deprivation and among some ethnic minority communities.

“To some extent, this lack of confidence in COVID-19 vaccinations was a global issue, fuelled by the rapid sharing of false information online,” Baroness Hallett stated. “However, it is clear that a lack of trust and confidence in authority was also a significant contributing factor in the UK.”

The report warns that the government must “rebuild trust” in vaccines before another pandemic strikes, as misinformation continues to spread globally through social media channels. It specifically urged all four UK nations to take proactive measures to build relationships with communities that demonstrated lower vaccine acceptance.

Despite these challenges, the inquiry characterized the UK vaccination program as an “extraordinary feat,” noting the country’s position as a world leader in biomedical sciences enabled rapid development and distribution of vaccines. By March 2023, an estimated 475,000 lives had been saved by vaccinations in England and Scotland alone, with millions more saved worldwide.

The report emphasized that the accelerated development of COVID-19 vaccines did not compromise safety standards, attributing the “remarkable pace” to decades of global research and preparation that preceded the pandemic.

However, the inquiry was critical of certain government decisions, particularly the mandatory vaccination requirements imposed on care home staff in England. Baroness Hallett concluded these mandates were “political and not led by clinical advice,” likely contributing to “alienation and increased vaccine hesitancy” among certain groups.

Another significant finding concerned individuals who suffered vaccine injuries. The inquiry found that the current compensation scheme has failed these individuals and requires urgent reform. Recommendations include nearly doubling the maximum payout from £120,000 to at least £200,000, introducing annual inflation-based increases, creating multiple payment levels based on injury severity, and eliminating the current threshold requiring applicants to be 60 percent disabled to receive compensation.

“The current scheme leaves those people with a significant injury that affects how they live, but does not meet the 60 percent threshold, with nothing,” the report stated.

As of January 2025, only 9,545 of the 17,519 applications to the vaccine damage payment scheme had received decisions, leaving nearly 8,000 applicants in limbo. More than 1,000 people have been waiting for over a year, with 126 waiting more than two years for a resolution.

The inquiry made five key recommendations, including reforming the payment scheme, giving regulatory bodies access to healthcare records for safety monitoring of new vaccines, establishing a “pharmaceutical expert advisory panel” to enhance the UK’s ability to develop and manufacture vaccines, creating targeted vaccine strategies, and improving monitoring of vaccine uptake.

The report also highlighted that vaccine hesitancy in certain communities was predictable and could have been better anticipated with proper planning. For many individuals, concerns centered on vaccine safety and potential side effects.

The government has reportedly spent £111 million responding to the inquiry, covering legal advice and staffing costs. By the end of December, the inquiry itself had spent just under £204 million, including expenses for setup, the chairwoman, lawyers, and public hearings across all four UK nations.

This fourth report from the UK COVID-19 Inquiry provides a comprehensive examination of the country’s handling of vaccines and therapeutics throughout the pandemic, offering crucial lessons for future public health emergencies.